Nephrotic syndrome

8 trials 6 recruiting MedDRA PT
8 Registered trials
6 Recruiting
8 Unique sponsors
7 Unique IMPs
3 Commercial trials
Drug classes (ATC)
— ATC code not specified 4
L Oncology (ATC L) 4
V Various (ATC V) 1
Mechanism of action (INN-stem analysis)
Unknown / small molecule 3 substances
Receptor fusion protein 1 substance
Immunosuppressant 1 substance
Monoclonal antibody (tumor, humanized) 1 substance
Monoclonal antibody (chimeric) 1 substance
Phase III: 4 Phase II: 4

Filter these 8 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 8 trials

Phase III

4 trials
  • F. Hoffmann-La Roche AG Commercial
    MYCOPHENOLATE MOFETIL; OBINUTUZUMAB
    2023-505140-19-00 6 countries 2023 n=26
    Recruiting
  • Amsterdam UMC Stichting Academic
    LEVAMISOLE HYDROCHLORIDE
    2024-517467-23-00 1 country 2024 n=87 Orphan
    Ended
  • Medical University Of Gdansk Academic
    RITUXIMAB
    2024-515058-26-00 1 country 2021 n=60
    Recruiting
  • Medical University Of Lodz Academic
    IMP not specified
    2023-509755-13-00 1 country 2025 n=70
    Recruiting

Phase II

4 trials
  • Synact Pharma ApS Commercial
    RESOMELAGON
    2024-518384-36-00 2 countries 2020 n=18
    Recruiting
  • Vera Therapeutics Inc. Commercial
    ATACICEPT
    2024-518465-10-00 6 countries 2025 n=124 Orphan
    Recruiting
  • Istituto Di Ricerche Farmacologiche Mario Negri Academic
    IOHEXOL; OBINUTUZUMAB
    2025-523306-33-00 1 country 2026 n=10 Orphan
    Recruiting
  • Ospedale Pediatrico Bambino Gesu Academic
    RITUXIMAB
    2024-511214-20-00 1 country n=80
    Not authorised
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Synact Pharma ApS Commercial 1 Phase II 1
Vera Therapeutics Inc. Commercial 1 Phase II 1
F. Hoffmann-La Roche AG Commercial 1 Phase III 1
Istituto Di Ricerche Farmacologiche Mario Negri Academic 1 Phase II 1
Ospedale Pediatrico Bambino Gesu Academic 1 Phase II 0
Amsterdam UMC Stichting Academic 1 Phase III 0
Medical University Of Gdansk Academic 1 Phase III 1
Medical University Of Lodz Academic 1 Phase III 1
New trials by year
2020
1
2021
1
2023
1
2024
1
2025
2
2026
1
← All indication landscapes